Skip to main content

The American Society of Gene and Cell Therapy (ASGCT) announced Jeffrey Chamberlain, PhD, endowed chair in Muscular Dystrophy, as the ASGCT vice president. Chamberlain will assume this role starting June 1, 2021, and will serve a three-year term. In 2022, he will serve as the president-elect and, in 2023, he will serve as the president.

ASGCT is the world’s largest professional organization focused on gene and cell therapies. The organization was formed by George Stamatoyannopoulos, former chief of Medical Genetics at UW.